SCHEMBL12349120

SCHEMBL12349120

Cc1cccc2c1sc1c(-c3ccc(-c4nc5ccccc5n4-c4ccccc4)cc3)cccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
RECQL P46063 1/20 0.44
HTT P42858 2/20 0.44
MAPK1 P28482 1/20 0.44
GRIA1 P42261 1/20 0.44
CACNG8 Q8WXS5 1/20 0.44
CACNG2 Q9Y698 1/20 0.44
ALDH1A1 P00352 6/20 0.40
GAA P10253 2/20 0.40
LMNA P02545 1/20 0.40
PTGS2 P35354 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 2/20 0.39
HSP90AA1 P07900 1/20 0.39
RAB9A P51151 1/20 0.39
PTGER4 P35408 1/20 0.39
PRKACA P17612 1/20 0.39
RPS6KB1 P23443 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1999345 0.93 ESR1 (0.54) ESR1ESR2RECQLHTTMAPK1
SCHEMBL12349242 0.91 ESR1 (0.45) ESR1ESR2RECQLHTTMAPK1
SCHEMBL16442540 0.88 ESR1 (0.46) ESR1ESR2RECQLHTTMAPK1
SCHEMBL430153 0.87 ESR1 (0.48) ESR1ESR2RECQLHTTMAPK1
SCHEMBL30350267 0.87 ESR1 (0.48) ESR1ESR2RECQLHTTMAPK1
SCHEMBL12568024 0.86 ESR1 (0.49) ESR1ESR2RECQLHTTMAPK1
SCHEMBL23169667 0.84 ESR1 (0.47) ESR1ESR2RECQLHTTMAPK1
SCHEMBL9288571 0.84 ESR1 (0.48) ESR1ESR2RECQLHTTMAPK1
SCHEMBL16692193 0.84 ESR1 (0.60) ESR1ESR2RECQLHTTMAPK1
SCHEMBL12349385 0.83 ESR2 (0.52) ESR1ESR2RECQLHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2662369-B1 Benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LAB (JP) 2015-09-23 EP disclosed
EP-2354135-B1 Benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LAB (JP) 2013-09-18 EP disclosed
US-8354542-B2 Heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-01-15 US disclosed
US-8354542-B2 Heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-01-15 US disclosed
EP-2354135-A1 benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-08-10 EP disclosed
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-06-23 US disclosed
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device CCNE2, CCNE1, CCNT1 ESR1 32/4885ESR2 216/4885RECQL 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.